Global Cold Sore Treatment (for HSV 1 Virus) Market, By Treatment Type (Medications, Applied Products, Cold Sore Patches, and Others(Non Medicated Products)), Route Of Administration (Oral, Topical, and Others), Mode Of Purchase (Over The Counter and Prescription Drug), Strain Type (Herpes Simplex Type 1 Virus and Herpes Simplex Type 2 Virus), Drug Type (Generic and Branded), Population Type (Adults, Pediatrics, and Geriatrics), Gender (Female and Male), End User (Home Healthcare, Hospitals, Specialty Clinics, and Others), Distribution Channel (Direct Tenders, Retail Sales, and Others) - Industry Trends and Forecast to 2031.
Cold Sore Treatment (for HSV 1 Virus) Market Analysis and Size
Global cold sore treatment (for HSV 1 virus) market is expected to gain market growth in the forecast period of 2024 to 2031.
Global cold sore treatment (for HSV 1 virus) market is driven by the high prevalence of both HSV-1 and H11 viruses is a major driver of the global cold sore treatment (for HSV 1 virus) market. HSV-1 is widespread, infecting an estimated 67% of the global population under 50 years of age. Similarly, H11 infections are common among poultry birds, with occasional transmission to humans.
This prevalence drives the demand for effective treatments. People with HSV-1 or H11 often experience recurrent cold sore outbreaks, which can be painful and unsightly. This creates strong consumer demand for treatments that can alleviate symptoms, reduce outbreak frequency, and prevent transmission. Changing lifestyles, including increased stress, fatigue, and sun exposure, can trigger outbreaks. The aging population is also more susceptible to cold sores, contributing to higher infection rates.
Data Bridge Market Research analyzes that the global cold sore treatment (for HSV 1 virus) market is growing with a CAGR of 6.6% in the forecast period of 2024 to 2031 and is expected to reach USD 1,501.88 million by 2031 from USD 927.29 million in 2023.
Report Metric
|
Details
|
Forecast Period
|
2024 to 2031
|
Base Year
|
2023
|
Historic Years
|
2022 (Customizable 2016-2021)
|
Quantitative Units
|
Revenue in USD Million
|
Segments Covered
|
Treatment Type (Medications, Applied Products, Cold Sore Patches, and Others(Non Medicated Products)), Route Of Administration (Oral, Topical, and Others), Mode Of Purchase (Over The Counter and Prescription Drug), Strain Type (Herpes Simplex Type 1 Virus and Herpes Simplex Type 2 Virus), Drug Type (Generic and Branded), Population Type (Adults, Pediatrics, and Geriatrics), Gender (Female and Male), End User (Home Healthcare, Hospitals, Specialty Clinics, and Others), Distribution Channel (Direct Tenders, Retail Sales, and Others)
|
Countries Covered
|
U.S., Canada, and Mexico, U.K., Germany, France, Spain, Italy, Belgium, Russia, Switzerland, Netherlands, Turkey, and rest of Europe, China, Australia, Japan, India, Singapore, South Korea, Malaysia, Thailand, Indonesia, Philippines, and rest of Asia-Pacific, Brazil, Argentina, and rest of South America, South Africa, Egypt, Saudi Arabia, U.A.E., and rest of Middle East and Africa
|
Market Players Covered
|
Fresenius SE & Co. KGaA, Zydus Pharmaceuticals, Inc., Teva Pharmaceuticals Industries Ltd., Novartis AG, Sun Pharmaceutical Industries Ltd., Quantum Health, GSK plc., Haleon Group of Companies, Church & Dwight Co., Inc., Hikma Pharmaceuticals PLC, Viatris Inc., Carma Labs Inc., URGO MEDICAL, Apotex Inc., Amneal Pharmaceuticals LLC, Blistex Inc., FOCUS CONSUMER HEALTHCARE, Hetero Healthcare Limited, Amparo medical Technologies, and Devirex AG among others
|
Market Definition
HSV-1, or herpes simplex virus type 1, is a common virus that causes cold sores, also known as fever blisters, on the lips and around the mouth. These sores are fluid-filled blisters that can be painful and may last for about 7-10 days.
Treatment for cold sores typically involves antiviral medications, such as acyclovir, famciclovir, or valacyclovir, which can help reduce the severity and duration of outbreaks. Over-the-counter creams and ointments, such as those containing docosanol or benzyl alcohol, can also provide relief from symptoms. Keeping the affected area clean and avoiding triggers, such as stress or sun exposure, can help prevent outbreaks.
Global Cold Sore Treatment (for HSV 1 Virus) Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail as below:
Drivers
- Growing Prevalence of Cold Sore Infection
The growing prevalence of cold sore infections, driven by changing lifestyles, aging population, increased awareness, and globalization, is a key driver of the global cold sore treatment (for HSV 1 virus) market. This trend is expected to continue, leading to further innovation and development of new treatment options for individuals affected by these infections.
- Growing Awareness about Cold Sore Symptoms and Treatment Options
The increased accessibility of information about cold sores through various media channels, such as the internet, social media, and healthcare campaigns, has raised awareness about the signs and symptoms of cold sores. This heightened awareness has resulted in more individuals seeking medical advice and treatment for their cold sores, which in turn, has driven market growth.
Opportunity
- Rising Advancements in Treatments for Cold Sore Infections
Breakthroughs in the treatment of cold sores (HSV-1) and herpes zoster (varicella-zoster virus) infections have led to the development of more potent antiviral medications with fewer side effects. Innovative drug delivery systems, such as liposomal formulations, have enhanced treatment efficacy and patient compliance.
Restraint/Challenge
- Increasing Complexity of Vaccine Development
Developing a vaccine to treat cold sores caused by the HSV-1 virus is met with considerable obstacles. One such challenge is the virus's ability to establish latency in nerve ganglia, making it difficult to target with vaccines as it remains dormant in inactive viral reservoirs. In addition, HSV-1's immune evasion mechanisms pose difficulties in inducing a robust and enduring immune response through vaccination. Despite these challenges, continued research and innovation are crucial to advancing vaccine development and reducing the burden of HSV-1 infections worldwide.
Recent Developments
- In August 2019, Sun Pharmaceutical Industries Ltd. reported that one of its subsidiaries has conceded a license agreement to a subsidiary of China medical system holding ltd. to develop and commercialize 7 generics drugs in China. This agreement helps the company to expand its business and make the product profile strong
- In November 2020, Amneal Pharmaceuticals LLC had declared the FDA approval of its Abbreviated New Drug Application (ANDA) for Acyclovir Cream, 5%. It is the generic version of Zovirax for treatment of herpes labialis in adolescents. The initiative by the company would result in increased distribution of the product, rise in brand recognition and rise in sales. This would result in positive growth of the market
- In August 2020, GSK completes acquisition of Affinivax, Inc. announced that it completed acquisition Cambridge, Massachusetts-based Affinivax, Inc. (Affinivax), a clinical-stage biopharmaceutical business. Next-generation pneumococcal vaccines are the most developed of a new class of vaccines that Affinivax lead the development of next-generation pneumococcal vaccines
Global Cold Sore Treatment (for HSV 1 Virus) Market Scope
Global cold sore treatment (for HSV 1 virus) market is segmented into nine notable segments based on treatment type, route of administration, mode of purchase, strain type, drug type, population type, gender, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the differences in your target markets.
Treatment Type
- Medications
- Applied Products
- Cold Sore Patches
- Others(Non Medicated Products)
On the basis of treatment type, the global cold sore treatment (for HSV 1 virus) market is segmented into medications, applied products, cold sore patches, and others (non medicated products).
Route of Administration
- Oral
- Topical
- Others
On the basis of route of administration, the global cold sore treatment (for HSV 1 virus) market is segmented into oral, topical, and others.
Mode of Purchase
- Over The Counter
- Prescription Drug
On the basis of mode of purchase, the global cold sore treatment (for HSV 1 virus) market is segmented over the counter and prescription drug.
Strain Type
- Herpes Simplex Type 1 Virus
- Herpes Simplex Type 2 Virus
On the basis of strain type, the global cold sore treatment (for HSV 1 virus) market is segmented into herpes simplex type 1 virus and herpes simplex type 2 virus.
Drug Type
- Generic
- Branded
On the basis of drug type, the global cold sore treatment (for HSV 1 virus) market is segmented into generic and branded.
Population Type
- Adults
- Pediatrics
- Geriatrics
On the basis of population type, the global cold sore treatment (for HSV 1 virus) market is segmented into adults, pediatrics, and geriatrics.
Gender
- Female
- Male
On the basis of gender, the global cold sore treatment (for HSV 1 virus) market is segmented into female and male.
End User
- Home healthcare
- Hospitals
- Specialty clinics
- Others
On the basis of end user, the global cold sore treatment (for HSV 1 virus) market is segmented into home healthcare, hospitals, specialty clinics, and others.
Distribution Channel
- Direct Tenders
- Retail sales
- Others
On the basis of distribution channel, the global cold sore treatment (for HSV 1 virus) market is segmented into direct tenders, retail sales, and others.
Global Cold Sore Treatment (for HSV 1 Virus) Market Regional Analysis/Insights
Global cold sore treatment (for HSV 1 virus) market is analyzed, and market size insights and trends are provided by based on treatment type, route of administration, mode of purchase, strain type, drug type, population type, gender, end user, and distribution channel as referenced above.
The countries covered in this global cold sore treatment (for HSV 1 virus) market report are U.S., Canada, and Mexico, U.K., Germany, France, Spain, Italy, Belgium, Russia, Switzerland, Netherlands, Turkey, and rest of Europe, China, Australia, Japan, India, Singapore, South Korea, Malaysia, Thailand, Indonesia, Philippines, and rest of Asia-Pacific, Brazil, Argentina, and rest of South America, South Africa, Egypt, Saudi Arabia, U.A.E., and rest of Middle East and Africa.
North America is expected to dominate the global cold sore treatment (for HSV 1 virus) market due to factors like high prevalence of cold sores, advanced healthcare infrastructure, strong consumer awareness and purchasing power, ongoing research and development initiatives, established marketing and distribution networks, and reduced stigma surrounding treatment-seeking behaviors.
U.S. is expected to dominate in the North America cold sore treatment (for HSV 1 virus) market due to factors such as large population, high healthcare expenditure, sophisticated healthcare system, extensive pharmaceutical industry, and widespread consumer awareness and access to cold sore treatments.
Germany is expected to dominate in the Europe cold sore treatment (for HSV 1 virus) market due to its advanced healthcare infrastructure, significant consumer demand for cold sore treatments, strong pharmaceutical industry, extensive research and development efforts, and well-established distribution networks, making it a hub for innovation and accessibility in cold sore management.
China is expected to dominate in the Asia-Pacific cold sore treatment (for HSV 1 virus) market due to its large population, increasing healthcare spending, expanding pharmaceutical industry, growing consumer awareness, and demand for cold sore treatments, coupled with a developing healthcare infrastructure and a rising prevalence of cold sores.
The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Cold Sore Treatment (for HSV 1 Virus) Market Share Analysis
Global cold sore treatment (for HSV 1 virus) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on the global cold sore treatment (for HSV 1 virus) market.
Some of the major players operating in the global cold sore treatment (for HSV 1 virus) market are Fresenius SE & Co. KGaA, Zydus Pharmaceuticals, Inc., Teva Pharmaceuticals Industries Ltd., Novartis AG, Sun Pharmaceutical Industries Ltd., Quantum Health, GSK plc., Haleon Group of Companies, Church & Dwight Co., Inc., Hikma Pharmaceuticals PLC, Viatris Inc., Carma Labs Inc., URGO MEDICAL, Apotex Inc., Amneal Pharmaceuticals LLC, Blistex Inc., FOCUS CONSUMER HEALTHCARE, Hetero Healthcare Limited, Amparo medical Technologies, and Devirex AG among others.
SKU-